Comparative Pharmacology
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus MEDIGESIC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXCEDRIN MIGRAINE RELIEF versus MEDIGESIC PLUS.
EXCEDRIN (MIGRAINE RELIEF) vs MEDIGESIC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: inhibits COX enzymes centrally, reducing prostaglandin synthesis; Aspirin: irreversibly acetylates COX-1 and COX-2, inhibiting prostaglandin synthesis and platelet aggregation; Caffeine: adenosine receptor antagonist, enhances analgesic effect by vasoconstriction and increased drug absorption.
Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis; chlorzoxazone acts centrally as a muscle relaxant via inhibition of polysynaptic reflexes at spinal and subcortical levels.
2 tablets (250 mg acetaminophen, 250 mg aspirin, 65 mg caffeine) orally every 6 hours as needed, not to exceed 6 tablets in 24 hours.
1-2 tablets orally every 4-6 hours as needed; maximum 8 tablets per day.
None Documented
None Documented
Acetaminophen: 2-3 hours (terminal); aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours (low dose), 15-30 hours (high dose); caffeine: 3-7 hours (adults). Clinical context: Half-lives prolonged in hepatic impairment, overdose, or renal failure.
Paracetamol: 2-3 hours. Pseudoephedrine: 5-8 hours (alkaline urine increases half-life). Chlorpheniramine: 12-15 hours in adults. Context: paracetamol half-life prolonged in hepatic impairment; pseudoephedrine/chlorpheniramine half-lives may be prolonged in renal impairment.
Renal excretion: acetaminophen ~3% unchanged, metabolites (glucuronide, sulfate, cysteine, mercapturate) ~85%; aspirin as salicylic acid ~10% unchanged, metabolites (salicyluric acid, glucuronides) ~75% renal; caffeine ~1-5% unchanged, metabolites (paraxanthine, theobromine, theophylline) ~70% renal. Biliary/fecal <5%.
Renal elimination of unchanged drug and metabolites: paracetamol ~90-100% (primarily as glucuronide and sulfate conjugates, ~5% unchanged), pseudoephedrine ~70-90% (mostly unchanged, dependent on urine pH), chlorpheniramine ~30-50% as metabolites. Biliary/fecal: minimal (<5%).
Category C
Category C
Analgesic Combination
Analgesic Combination